Kymera Therapeutic/KYMR

$43.25

-0.73%
-
1D1W1MYTD1YMAX

About Kymera Therapeutic

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling and Quantitative System Pharmacology Model. The Company’s clinical-stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). The Company’s programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Ticker

KYMR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nello Mainolfi

Employees

187

Headquarters

Watertown, United States

KYMR Metrics

BasicAdvanced
$2.65B
Market cap
-
P/E ratio
-$2.52
EPS
2.30
Beta
-
Dividend rate

What the Analysts think about KYMR

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 13 analysts.
13.48% upside
High $112.00
Low $30.00
$43.25
Current price
$49.08
Average price target

KYMR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-29.91% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$47.8M
917.02%
Net income
$-14.3M
-72.92%
Profit margin
-29.91%
-97.34%

KYMR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 40.33%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.70
-$0.67
-$0.90
-
Expected
-$0.68
-$0.64
-$0.64
-$0.72
Surprise
3.33%
5.24%
40.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Kymera Therapeutic stock

Buy or sell Kymera Therapeutic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing